Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of ...

Teva Pharmaceutical Industries Ltd. ADR 1.42% $19.56B ...

a global biopharma company to unite science ... will be the first greenfield pharmaceutical manufacturing site that GSK has built globally over the past ten years. It is also the first facility ...

The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Depemokimab (GSK-3511294) is under development for the ...

After hours: December 11 at 6:07:08 PM EST Loading Chart for AYTU ...

GSK licensed the drug from longstanding partner Ionis as part of a two-drug deal in 2019, paying $25 million upfront with milestone payments taking the value of the deal up to $262 million.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

GSK had been expecting approval only for second-line use in patients previously treated with Jakafi or other JAK drugs, like Bristol Myers Squibb's Inrebic (fedratinib) and CTI Biopharma's Vonjo ...

India is keen to expand its manufacturing sector, with a focus on diversifying into newer lines of production, advancing the industrial capacity of traditional sectors like automobiles, and ...

With global spending on prescription drugs increasing by 6% annually since 2019, it’s no surprise that the biopharmaceuticals industry is growing—and it’s expected to keep growing ...